A Phase 4 interventional study of Atazanavir and Ritonavir in HIV, Pediatric, sponsored by Bristol-Myers Squibb. Completed at 27 sites in 8 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-04-27.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to collect safety clinical data in HIV-infected pediatric patients aged 6 and older to younger than18 years and weighing 15 kg or more, who are receiving atazanavir capsule boosted with ritonavir and an optimized nucleoside reverse transcriptase inhibitor backbone therapy as part of their antiretroviral regimen.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One of the following cardiac rhythm abnormalities documented on the screening :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with baseline weight of 15 to \<20 kg received 150 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
Drug: Atazanavir · Drug: Ritonavir
Participants with baseline weight of 20 to \<40 kg received 200 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
Drug: Atazanavir · Drug: Ritonavir
Participants with baseline weight ≥ 40 kg received 300 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
Drug: Atazanavir · Drug: Ritonavir
Also known as: Reyataz, BMS-232632
Also known as: Norvir
Number of Participants Who Died and With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Grade 2-4 Related AEs, Grade 3-4 AEs, and Centers for Disease Control (CDC) Class C AIDS Events
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death.
Time frame: From first dose to last dose plus 30 days (assessed up to February 2017, approximately 42 months)
Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormal, Grades 1-4
Hematocrit (%): Grade (Gr) 1= ≥28.5- \<31.5; Gr 2= ≥24- \<28.5; Gr 3= ≥19.5- \<24; Gr 4= \<19.5. Hemoglobin (g/dL): Grade (Gr)1=8.5-10.0; Gr 2=7.5-8.4; Gr 3=6.50-7.4; Gr 4= \<6.5. Platelets (/mm\^3): Gr 1=100,000-124,999; Gr 2=50,000-99,999; Gr 3=25,000-49,999; Gr 4= \<25,000. White blood cells (/mm\^3): Gr 1=2000-2500; Gr 2=1500-1999; Gr 3=1000-1499; Gr 4= \<1000. Neutrophils (/mm\^3): Gr 1=1000-1500; Gr 2= ≥750-1000; Gr 3= ≥500-750; Gr 4= \<500. Alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate transaminase (AST) (\*upper limit of normal \[ULN\]): Gr 1=1.5-2.5; Gr 2=2.6-5.0; Gr 3=5.1-10.0; Gr 4= \>10.0. Total bilirubin (adult and pediatric \>14 days) (\*ULN): Gr 1=1.1-1.5; Gr 2=1.6-2.5; Gr 3=2.6-5.0; Gr 4= \>5.0. Albumin (g/dL): Gr 1= 3.1- \<LLN; Gr 2=2.0-2.9; Gr 3= \<2.0; Gr 4=NA. Amylase (\*ULN): Gr 1=1.10-1.39; Gr 2=1.40-2.09; Gr 3=2.10-5.0; Gr 4= \>5. Lipase (\*ULN): Gr 1=1.1-1.5; Gr 2=1.6-3.0; Gr 3=3.1-5.0; Gr 4= \>5.0.
Time frame: After first dose to last dose plus 30 days (assessed up to February 2017, approximately 42 months)
Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormal, Grades 1-4 (Continued)
Blood urea nitrogen (\*upper limit of normal \[ULN\]): Grade (Gr) 1=1.25-2.5; Gr 2=2.6-5.0; Gr 3=5.1-10; Gr 4= \>10. Uric acid (mg/dL): Gr 1=7.5-10.0; Gr 2=10.1-12; Gr 3=12.1-15.0; Gr 4= \>15.0. Bicarbonate (mEqL): Gr 1= 19.0-21.0; Gr 2=15.0-18.0; Gr 3=41-45; Gr 4= \>45. Calcium, low (mg/dL): Gr 1=7.8-8.4; Gr 2=7.0-7.7; Gr 3=6.1-6.9; Gr 4= \<6.1.Potassium (mEq/L), high: Gr 1=5.6-6.0; Gr 2=6.1-6.5; Gr 3=6.6-7.0; Gr 4= \>7.0. Potassium (mEq/L), low: Gr 1=3.1-3.4; Gr 2=2.5-2.9; Gr 3=2.0-2.4; Gr 4= \<2.0. Sodium (mEq/L), low: Gr 1=130-135; Gr 2=125-129; Gr 3=121-124; Gr 4= \<1. Total cholesterol, fasting (mg/dL): Gr 1=200-239; Gr 2=240-300; Gr 3= \>300; Gr 4=Not applicable (NA). Low-density lipoprotein (LDL) cholesterol, fasting (mg/dL): Gr 1=130-159; Gr 2=160-190; Gr 3= \>190; Gr 4= NA. Glucose, low (mg/dL): Gr 1= 55-64; Gr 2=40-54; Gr 3=30-39; Gr 4= \<30. Glucose, fasting (mg/dL): Gr 1=110-125; Gr 2=126-250; Gr 3=251-500; Gr 4 \>500.
Time frame: After first dose to last dose plus 30 days (assessed up to February 2017, approximately 42 months)
| Milestone | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) |
|---|---|---|---|
| Started | 3 | 33 | 23 |
| Completed | 2 | 15 | 13 |
| Not completed | 1 | 18 | 10 |
| Withdrew: Poor/non-compliance | 1 | 4 | 1 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 7 | 1 |
| Withdrew: Participant request to discontinue | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Completed only first 24 weeks of study | 0 | 2 | 3 |
| Withdrew: Did not complete first 24 weeks of study | 0 | 3 | 3 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death.
| Participants | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) |
|---|---|---|---|
| Deaths | 0 | 0 | 1 |
| SAEs | 1 | 3 | 4 |
| AEs leading to discontinuation | 0 | 1 | 2 |
| Grade 2-4 related AEs | 1 | 3 | 5 |
| Grade 3-4 AEs | 0 | 3 | 5 |
| CDC Class C AIDS events | 0 | 1 | 0 |
Hematocrit (%): Grade (Gr) 1= ≥28.5- \<31.5; Gr 2= ≥24- \<28.5; Gr 3= ≥19.5- \<24; Gr 4= \<19.5. Hemoglobin (g/dL): Grade (Gr)1=8.5-10.0; Gr 2=7.5-8.4; Gr 3=6.50-7.4; Gr 4= \<6.5. Platelets (/mm\^3): Gr 1=100,000-124,999; Gr 2=50,000-99,999; Gr 3=25,000-49,999; Gr 4= \<25,000. White blood cells (/mm\^3): Gr 1=2000-2500; Gr 2=1500-1999; Gr 3=1000-1499; Gr 4= \<1000. Neutrophils (/mm\^3): Gr 1=1000-1500; Gr 2= ≥750-1000; Gr 3= ≥500-750; Gr 4= \<500. Alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate transaminase (AST) (\*upper limit of normal \[ULN\]): Gr 1=1.5-2.5; Gr 2=2.6-5.0; Gr 3=5.1-10.0; Gr 4= \>10.0. Total bilirubin (adult and pediatric \>14 days) (\*ULN): Gr 1=1.1-1.5; Gr 2=1.6-2.5; Gr 3=2.6-5.0; Gr 4= \>5.0. Albumin (g/dL): Gr 1= 3.1- \<LLN; Gr 2=2.0-2.9; Gr 3= \<2.0; Gr 4=NA. Amylase (\*ULN): Gr 1=1.10-1.39; Gr 2=1.40-2.09; Gr 3=2.10-5.0; Gr 4= \>5. Lipase (\*ULN): Gr 1=1.1-1.5; Gr 2=1.6-3.0; Gr 3=3.1-5.0; Gr 4= \>5.0.
| Participants | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) |
|---|---|---|---|
| Hematocrit | 0 | 3 | 0 |
| Hemoglobin | 0 | 5 | 0 |
| Platelets | 0 | 0 | 1 |
| White blood cells | 0 | 3 | 0 |
| Neutrophils+bands (absolute) | 1 | 13 | 4 |
| ALT | 1 | 6 | 9 |
| AST | 0 | 6 | 5 |
| ALP | 1 | 11 | 12 |
| Total bilirubin | 3 | 26 | 17 |
| Albumin | 2 | 15 | 6 |
| Amylase | 2 | 27 | 14 |
| Lipase | 0 | 15 | 8 |
Blood urea nitrogen (\*upper limit of normal \[ULN\]): Grade (Gr) 1=1.25-2.5; Gr 2=2.6-5.0; Gr 3=5.1-10; Gr 4= \>10. Uric acid (mg/dL): Gr 1=7.5-10.0; Gr 2=10.1-12; Gr 3=12.1-15.0; Gr 4= \>15.0. Bicarbonate (mEqL): Gr 1= 19.0-21.0; Gr 2=15.0-18.0; Gr 3=41-45; Gr 4= \>45. Calcium, low (mg/dL): Gr 1=7.8-8.4; Gr 2=7.0-7.7; Gr 3=6.1-6.9; Gr 4= \<6.1.Potassium (mEq/L), high: Gr 1=5.6-6.0; Gr 2=6.1-6.5; Gr 3=6.6-7.0; Gr 4= \>7.0. Potassium (mEq/L), low: Gr 1=3.1-3.4; Gr 2=2.5-2.9; Gr 3=2.0-2.4; Gr 4= \<2.0. Sodium (mEq/L), low: Gr 1=130-135; Gr 2=125-129; Gr 3=121-124; Gr 4= \<1. Total cholesterol, fasting (mg/dL): Gr 1=200-239; Gr 2=240-300; Gr 3= \>300; Gr 4=Not applicable (NA). Low-density lipoprotein (LDL) cholesterol, fasting (mg/dL): Gr 1=130-159; Gr 2=160-190; Gr 3= \>190; Gr 4= NA. Glucose, low (mg/dL): Gr 1= 55-64; Gr 2=40-54; Gr 3=30-39; Gr 4= \<30. Glucose, fasting (mg/dL): Gr 1=110-125; Gr 2=126-250; Gr 3=251-500; Gr 4 \>500.
| Participants | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) |
|---|---|---|---|
| Blood urea nitrogen | 0 | 3 | 0 |
| Uric acid | 0 | 2 | 3 |
| Bicarbonate, low | 3 | 29 | 17 |
| Calcium, low | 0 | 2 | 3 |
| Potassium, high | 0 | 2 | 1 |
| Potassium, low | 0 | 2 | 0 |
| Total cholesterol, fasting (n=3, 31, 21) | 0 | 10 | 6 |
| Sodium, low | 1 | 13 | 0 |
| LDL cholesterol, fasting (n=3, 31, 21) | 0 | 7 | 3 |
| Glucose, low (n=1, 11, 9) | 0 | 3 | 0 |
| Glucose, fasting, high (3, 31, 22) | 0 | 3 | 1 |
| Calcium, high | 0 | 2 | 0 |
| Chloride, high | 0 | 0 | 2 |
| Chloride, low | 0 | 0 | 0 |
| Glucose, Non-Fasting, High | 0 | 0 | 0 |
| Sodium, high | 0 | 1 | 1 |
| Creatinine | 0 | 1 | 0 |
| Triglycerides, fasting | 0 | 0 | 0 |
Collected over From first dose to last dose plus 30 days (assessed up to February 2017, approximately 42 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B/L Weight 15 to Less Than 20 kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| B/L Weight 20 to Less Than 40 kg | 0/33 (0%) | 3/33 (9.1%) | 26/33 (78.8%) |
| B/L Weight Greater Than and Equal 40 kg | 1/23 (4.3%) | 4/23 (17.4%) | 20/23 (87%) |
| Event | B/L Weight 15 to Less Than 20 kg | B/L Weight 20 to Less Than 40 kg | B/L Weight Greater Than and Equal 40 kg |
|---|---|---|---|
| Accidental overdoseInjury, poisoning and procedural complications | 1/3 | 0/33 | 0/23 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/33 | 1/23 |
| AppendicitisInfections and infestations | 0/3 | 0/33 | 1/23 |
| Meningitis bacterialInfections and infestations | 0/3 | 0/33 | 1/23 |
| Abnormal behaviourPsychiatric disorders | 0/3 | 0/33 | 1/23 |
| OverdoseInjury, poisoning and procedural complications | 0/3 | 1/33 | 0/23 |
| SeizureNervous system disorders | 0/3 | 1/33 | 0/23 |
| GlomerulonephritisRenal and urinary disorders | 0/3 | 1/33 | 0/23 |
| HaematuriaRenal and urinary disorders | 0/3 | 1/33 | 0/23 |
| Post streptococcal glomerulonephritisRenal and urinary disorders | 0/3 | 1/33 | 0/23 |
| Event | B/L Weight 15 to Less Than 20 kg | B/L Weight 20 to Less Than 40 kg | B/L Weight Greater Than and Equal 40 kg |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/3 | 13/33 | 4/23 |
| JaundiceHepatobiliary disorders | 1/3 | 2/33 | 6/23 |
| BronchitisInfections and infestations | 1/3 | 2/33 | 0/23 |
| GastroenteritisInfections and infestations | 1/3 | 3/33 | 0/23 |
| InfluenzaInfections and infestations | 1/3 | 3/33 | 3/23 |
| NasopharyngitisInfections and infestations | 1/3 | 3/33 | 6/23 |
| Otitis mediaInfections and infestations | 1/3 | 2/33 | 2/23 |
| TonsillitisInfections and infestations | 1/3 | 4/33 | 0/23 |
| PharyngitisInfections and infestations | 1/3 | 1/33 | 0/23 |
| PharyngotonsillitisInfections and infestations | 1/3 | 0/33 | 0/23 |
All participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) | Total |
|---|---|---|---|---|
| Mean | 6.0 ± 0.0 | 10.7 ± 2.67 | 14.7 ± 1.72 | 12.0 ± 3.26 |
| Age, Customized(Years) | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) | Total |
|---|---|---|---|---|
| Median | 6.0 (6 to 6) | 11.0 (6 to 16) | 15.0 (11 to 17) | 12.0 (6 to 17) |
| Sex: Female, Male(Participants) | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) | Total |
|---|---|---|---|---|
| Female | 2 | 17 | 11 | 30 |
| Male | 1 | 16 | 12 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 2 | 3 |
| Not Hispanic or Latino | 1 | 2 | 2 | 5 |
| Unknown or Not Reported | 2 | 30 | 19 | 51 |
| Race/Ethnicity, Customized(Participants) | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) | Total |
|---|---|---|---|---|
| White | 1 | 5 | 4 | 10 |
| Black/African American | 2 | 24 | 9 | 35 |
| Other | 0 | 4 | 10 | 14 |
| Region of Enrollment(Participants) | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) | Total |
|---|---|---|---|---|
| Africa | 2 | 24 | 8 | 34 |
| Europe | 0 | 1 | 0 | 1 |
| North America | 1 | 0 | 3 | 4 |
| South America | 0 | 8 | 12 | 20 |
| Country(Participants) | Atazanavir, 150 mg + Ritonavir, 100 mg (Weight: 15 to <20 kg) | Atazanavir, 200 mg + Ritonavir, 100 mg (Weight: 20 to <40 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: ≥40 kg) | Total |
|---|---|---|---|---|
| Argentina | 0 | 3 | 0 | 3 |
| Brazil | 0 | 3 | 4 | 7 |
| Chile | 0 | 1 | 2 | 3 |
| Mexico | 1 | 0 | 1 | 2 |
| Peru | 0 | 1 | 6 | 7 |
| Russia | 0 | 1 | 0 | 1 |
| South Africa | 2 | 24 | 8 | 34 |
| United States | 0 | 0 | 2 | 2 |
Ran from Nov 2012 to primary completion in Oct 2014, 23 months.
Results were first posted in Nov 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atazanavir · Ritonavir